Nanoparticle-Mediated Target Delivery of TRAIL as Gene Therapy for Glioblastoma

Kui Wang, Forrest M. Kievit, Mike Jeon, John R. Silber, Richard G. Ellenbogen, Miqin Zhang

Research output: Contribution to journalArticlepeer-review

51 Scopus citations

Abstract

Human tumor necrosis factor α-related apoptosis-inducing ligand (TRAIL) is an attractive cancer therapeutic because of its ability to induce apoptosis in tumor cells while having a negligible effect on normal cells. However, the short serum half-life of TRAIL and lack of efficient in vivo administration approaches have largely hindered its clinical use. Using nanoparticles (NPs) as carriers in gene therapy is considered as an alternative approach to increase TRAIL delivery to tumors as transfected cells would be induced to secrete TRAIL into the tumor microenvironment. To enable effective delivery of plasmid DNA encoding TRAIL into glioblastoma (GBM), we developed a targeted iron oxide NP coated with chitosan-polyethylene glycol-polyethyleneimine copolymer and chlorotoxin (CTX) and evaluated its effect in delivering TRAIL in vitro and in vivo. NP-TRAIL successfully delivers TRAIL into human T98G GBM cells and induces secretion of 40 pg mL-1 of TRAIL in vitro. Transfected cells show threefold increased apoptosis as compared to the control DNA bound NPs. Systemic administration of NP-TRAIL-CTX to mice bearing T98G-derived flank xenografts results in near-zero tumor growth and induces apoptosis in tumor tissue. Our results suggest that NP-TRAIL-CTX can potentially serve as a targeted anticancer therapeutic for more efficient TRAIL delivery to GBM.

Original languageEnglish (US)
Pages (from-to)2719-2726
Number of pages8
JournalAdvanced Healthcare Materials
Volume4
Issue number17
DOIs
StatePublished - Dec 9 2015
Externally publishedYes

Keywords

  • Apoptosis
  • Gene therapy
  • Glioblastoma
  • TRAIL
  • Transfection

ASJC Scopus subject areas

  • Biomaterials
  • Biomedical Engineering
  • Pharmaceutical Science

Fingerprint

Dive into the research topics of 'Nanoparticle-Mediated Target Delivery of TRAIL as Gene Therapy for Glioblastoma'. Together they form a unique fingerprint.

Cite this